In July 2013, the FDA granted approval for afatinib, an irreversible inhibitor of the ErbB family of tyrosine kinases, which binds to EGFR, HER2, and HER4, irreversibly inhibiting tyrosine kinase autophosphorylation, for the first-line treatment of EGFR mutation-positive metastatic NSCLC [20]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.